Lara Morales, APRN
Primary Care · Sparks, NVNPI 1427660992
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 328 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 328 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$862
- Novo Nordisk$555
- GSK$479
- Pfizer$479
- Lilly USA, LLC$387
- plus $2K from 24 others
What the payments were for
- Food & beverage$6,266100%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 80 | $1,449 |
| AstraZeneca | 42 | $862 |
| Novo Nordisk | 31 | $555 |
| GSK | 24 | $479 |
| Pfizer | 27 | $479 |
| Lilly USA, LLC | 23 | $387 |
| Amgen | 15 | $370 |
| Merck | 12 | $244 |
| Idorsia Pharmaceuticals US Inc | 11 | $163 |
| Johnson & Johnson(2 entities) | 3 | $155 |
| Boehringer Ingelheim | 9 | $145 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $121 |
| Bayer | 6 | $105 |
| Scilex Pharmaceuticals Inc. | 5 | $94 |
| Otsuka America Pharmaceutical, Inc. | 4 | $92 |
| Astellas Pharma US Inc | 3 | $84 |
| Exact Sciences | 5 | $79 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $74 |
| Corcept Therapeutics | 4 | $64 |
| Phathom Pharmaceuticals, Inc. | 3 | $53 |
| Medtronic | 2 | $49 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| Mayne Pharma Commercial LLC | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Tactile Systems Technology Inc | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,275 in reported general payments places this provider in the 95th percentile of 81 primary care providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 28 | $44,368 |
| FarxigaDapagliflozin Propanediol | 21 | $31,504 |
| OzempicSemaglutide | 17 | $25,252 |
| EliquisApixaban | 11 | $18,542 |
| LinzessLinaclotide | 13 | $7,911 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 19 | $3,970 |
| Atorvastatin Calcium | 211 | $3,681 |
| Estradiol | 36 | $2,641 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 89 | $2,516 |
| Levothyroxine Sodium | 174 | $1,535 |
| Pregabalin | 11 | $1,419 |
| Losartan Potassium | 113 | $1,412 |
| Trazodone Hcl | 96 | $1,326 |
| Tamsulosin Hcl | 52 | $1,311 |
| Omeprazole | 105 | $1,102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $145 | $44,36828 claims |
| AstraZenecaFarxiga | $862 | $31,50421 claims |
| Novo NordiskOzempic | $555 | $25,25217 claims |
| PfizerEliquis | $479 | $18,54211 claims |
| AbbVieLinzess | $1,449 | $7,91113 claims |
| GSKShingrix | $479 | $3,97019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 81 primary care providers in Nevada.
Other primary care in Sparks
- Jennifer CribbLas Vegas$7K
- Ruel MarianoLas Vegas$4K
- George Gabriel ToldnessLas Vegas$4K
- William EmmerlingHenderson$3K
- Jona SteadLas Vegas$3K
- Mario LuglioLas Vegas$3K
- Jocybel ItorralbaLas Vegas$3K
- Jerifaye FloresLas Vegas$2K
- Sneha ThomasLas Vegas$2K
- Alexandria LightningHenderson$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.